You are here

  • Home
  • Archive
  • Volume 12, Issue 5
  • Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro)

Article metrics

Article menu

Download PDFPDF

Diabetes and endocrinology
Original research
Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro)

 

Online download statistics by month:

Online download statistics by month: May 2022 to October 2024

AbstractFullPdf
May 202245645568
Jun 202224124480
Jul 202217717239
Aug 202211211426
Sep 202225725229
Oct 2022999318
Nov 2022949341
Dec 2022464511
Jan 2023454422
Feb 2023313228
Mar 2023666927
Apr 2023373710
May 2023555524
Jun 2023444410
Jul 2023404058
Aug 2023424262
Sep 2023514648
Oct 2023302735
Nov 2023474616
Dec 2023373328
Jan 2024615617
Feb 2024605914
Mar 2024394044
Apr 2024464322
May 2024373716
Jun 2024363532
Jul 2024333151
Aug 2024282114
Sep 2024222220
Oct 2024221
Total23712329911